What has changed in Lyme disease treatment over the past 15 years? Could herbal supplements, emerging medications, and new diagnostic technologies help physicians better understand persistent symptoms and complex tick-borne infections?
In this LIVE from ILADS episode of the Tick Boot Camp Podcast, co-host Rich Johannesen sits down with Dr. Samuel “Sam” Shor, MD, FILADS, a pioneering Lyme disease physician, researcher, former president of the International Lyme and Associated Diseases Society (ILADS), and recipient of the 2025 Pioneer in Lyme Award.
Recorded at the 2025 ILADS Conference in San Antonio, Texas, this conversation explores Dr. Shor’s decades of experience studying chronic fatigue syndrome, Lyme disease, and associated tick-borne infections.
Dr. Shor discusses the evolution of his clinical approach, including the growing role of nutraceuticals, research into disulfiram for Borrelia persister cells, and the increasing recognition of patients with multiple tick-borne infections.
He also explains how clinicians can use symptom patterns to investigate the three Bs—Borrelia, Bartonella, and Babesia—and discusses emerging laboratory technologies such as PCR, FISH, and urine antigen testing.
The interview concludes with a celebration of Dr. Shor’s contributions to Lyme disease research, medical education, and patient advocacy as he prepares to receive one of ILADS’ most significant honors.
For patients who have spent years searching for answers, Dr. Shor’s work represents decades of commitment to understanding persistent illness and advancing the conversation around Lyme disease.
Meet Dr. Samuel Shor, MD, FILADS
Dr. Samuel Shor is an internal medicine physician whose interest in chronic fatigue and complex illness began in the late 1980s.
His clinical experiences eventually led him to investigate possible relationships between chronic fatigue syndrome and Lyme disease.
Over the following decades, he became involved in Lyme disease research, medical education, and advocacy.
His professional contributions include:
- Serving as president of ILADS
- Contributing to peer-reviewed research on Lyme disease
- Leading the development of an ILADS definition of chronic Lyme disease
- Investigating the relationship between chronic fatigue syndrome and Lyme disease
- Studying integrative treatment approaches involving nutraceuticals
- Educating clinicians about Lyme disease and associated infections
- Advocating for greater recognition of patients with persistent symptoms
Dr. Shor has also participated in public policy and educational initiatives, including presentations on Capitol Hill and service on the Virginia Governor’s Task Force on Lyme Disease.
His contributions have helped shape discussions about the diagnosis, treatment, and research priorities surrounding persistent Lyme disease symptoms.
From Chronic Fatigue Syndrome to Lyme Disease Research
Dr. Shor explains that his interest in complex chronic illness began early in his medical career.
During the late 1980s, he encountered patients experiencing persistent fatigue and other symptoms that were difficult to explain.
He became particularly interested in chronic fatigue syndrome, now commonly referred to as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Over time, he began investigating whether Lyme disease might be contributing to symptoms in some of these patients.
During the interview, Dr. Shor references research involving more than 200 patients with chronic fatigue syndrome.
He explains that his findings suggested an association between Lyme disease and symptoms experienced by a substantial portion of this patient population.
His work contributed to his growing interest in chronic Lyme disease and the need for further research into persistent symptoms.
ME/CFS and Lyme disease are distinct diagnoses, and research has not established that most cases of ME/CFS are caused by Lyme disease.
However, overlapping symptoms such as fatigue, cognitive difficulties, pain, and reduced physical functioning can make differential diagnosis challenging.
Dr. Shor’s experience illustrates how investigating unexplained symptoms can generate important clinical and research questions.
How Lyme Disease Treatment Has Evolved
Rich asks Dr. Shor how his treatment approach has changed over the past 15 years.
Dr. Shor explains that his understanding of Lyme disease and associated infections has evolved alongside new research.
He continues to recognize antimicrobial medications as an important component of treatment for appropriately diagnosed bacterial infections.
However, he also discusses the growing role of complementary approaches in his practice.
One area of particular interest is nutraceuticals, including herbal products and nutritional supplements.
Dr. Shor describes using these products as adjunctive therapies and, in some circumstances, as part of longer-term management strategies.
He emphasizes that he does not want to use antibiotics longer than necessary.
His goal is to consider different treatment options while balancing potential benefits and risks.
The effectiveness of individual nutraceuticals for persistent Lyme disease symptoms remains uncertain, and supplements should not be assumed to eliminate Borrelia or other infections.
What Are Nutraceuticals?
During the interview, Rich asks Dr. Shor to explain the term nutraceutical.
Dr. Shor describes nutraceuticals as products such as:
- Herbal preparations
- Nutritional supplements
- Other nonprescription products used to support health
These products are sometimes incorporated into integrative treatment plans.
Dr. Shor explains that he has become increasingly interested in their potential role alongside or following conventional antimicrobial treatment.
However, over-the-counter availability does not establish that a product is safe or effective.
Herbal products and supplements can cause adverse effects, interact with medications, and vary in quality and composition.
Patients should discuss supplements with qualified healthcare professionals, particularly when managing multiple medications or medical conditions.
Disulfiram and Borrelia Persister Cells
One of the most scientifically interesting portions of the interview focuses on disulfiram, a medication traditionally used in the treatment of alcohol use disorder.
Dr. Shor explains that laboratory researchers have investigated disulfiram’s activity against Borrelia burgdorferi.
He is particularly interested in research involving bacterial persister cells.
Persister cells are bacterial populations that can survive exposure to certain antimicrobial treatments under laboratory conditions.
Researchers have investigated whether these cells may contribute to difficulties eliminating Borrelia under some circumstances.
Dr. Shor describes laboratory findings suggesting that disulfiram may have activity against certain Borrelia forms.
These discoveries have encouraged further investigation into whether the medication might have clinical applications for patients experiencing persistent symptoms after Lyme disease treatment.
An important distinction: Activity against bacteria in a laboratory does not establish that a medication is effective or safe for treating patients.
Disulfiram is not FDA-approved for Lyme disease.
A small published pilot study involving patients with persistent symptoms after Lyme disease treatment identified possible improvements in some participants but also significant tolerability and safety concerns.
Disulfiram can cause serious adverse effects, including neurological complications, liver injury, and interactions with alcohol and other substances.
Its use for Lyme disease remains investigational and requires careful medical oversight.
Are Patients Being Diagnosed With More Tick-Borne Coinfections?
Rich raises a question based on Tick Boot Camp’s extensive interview experience.
After speaking with hundreds of patients, he has observed that more recent guests frequently report diagnoses involving multiple infections rather than Borrelia alone.
He asks Dr. Shor whether the change reflects:
- More pathogens circulating in ticks
- Increased exposure to infected ticks
- Improvements in diagnostic testing
- Greater clinical awareness of coinfections
Dr. Shor believes several factors may be contributing.
He explains that researchers are identifying multiple organisms in ticks and that clinicians are increasingly evaluating patients for additional infections.
He also emphasizes the importance of recognizing clinical features that may suggest particular pathogens.
The frequency of multiple positive test results in a specialty practice or podcast population does not establish that most Lyme disease patients have several active infections.
Nevertheless, coinfections are an important consideration when a patient’s symptoms, exposure history, and diagnostic findings support further evaluation.
The Three Bs: Borrelia, Bartonella, and Babesia
Dr. Shor discusses three organisms frequently considered during evaluations for Lyme disease and associated infections.
He explains that different infections may produce overlapping symptoms but can also have distinguishing clinical features.
Borrelia: Migrating Joint Pain
Borrelia burgdorferi is the primary cause of Lyme disease in the United States.
Dr. Shor highlights migratory polyarthralgia, meaning pain affecting multiple joints that changes location.
For example, a patient might experience pain in one knee on a particular day and pain in an elbow or another joint later.
Migrating joint pain can occur in Lyme disease, although it is not exclusive to Lyme and does not establish a diagnosis on its own.
Bartonella: Foot Pain and Urinary Symptoms
Dr. Shor describes observing certain symptoms among patients he evaluates for Bartonella, including:
- Pain in the bottoms of the feet
- Urinary urgency
- Urinary frequency
- Bladder irritation
He explains that these features may prompt him to investigate Bartonella.
However, these symptoms have many potential causes and are not validated diagnostic indicators of Bartonella infection.
Bartonella species can cause several recognized human diseases, but their proposed role in many chronic multisystem symptom presentations remains under investigation.
Babesia: Night Sweats and Air Hunger
Babesia is a group of parasites that infect red blood cells.
Dr. Shor highlights two symptoms he considers particularly relevant:
Profuse sweating: Some patients experience significant night sweats, sometimes requiring them to change clothing.
Air hunger: Patients may describe difficulty taking a satisfying deep breath.
Babesiosis can cause fever, chills, sweats, fatigue, and other symptoms. Severe cases may involve anemia and serious complications.
Air hunger is a nonspecific symptom and can also occur with cardiovascular, pulmonary, autonomic, and other medical conditions.
New or significant breathing difficulties require prompt medical evaluation.
Dr. Shor emphasizes that patients do not need to experience every characteristic symptom to have a particular infection.
Why Clinical History Matters
Dr. Shor explains that recognizing symptom patterns can help clinicians determine which infections to investigate.
A patient with migrating joint pain may warrant evaluation for Lyme disease when the exposure history and clinical findings are consistent.
Another patient with fever, sweats, and appropriate tick exposure may require evaluation for babesiosis or other infections.
The purpose of recognizing patterns is to guide further investigation, not replace diagnostic testing or establish a diagnosis from symptoms alone.
His discussion reinforces the importance of combining medical history, physical examination, exposure assessment, and appropriate laboratory testing.
The Limitations of Lyme Disease Antibody Testing
Rich asks Dr. Shor about developments in diagnostic testing.
Dr. Shor discusses the traditional two-tier antibody testing approach used in Lyme disease diagnosis.
Conventional two-tier testing involves an initial immunoassay followed by a second antibody test when indicated.
Modified two-tier testing using two immunoassays is also recommended in appropriate circumstances.
Dr. Shor expresses concern about the sensitivity of antibody-based testing and argues that some infections may be missed.
He cites an approximately 50% sensitivity figure during the interview.
That figure should not be interpreted as the overall sensitivity of all currently recommended Lyme disease testing methods.
Sensitivity varies substantially by disease stage and clinical presentation. Antibody tests are less sensitive early in infection, before a measurable immune response develops, but perform substantially better in many later manifestations.
An important limitation of antibody testing is that antibodies can remain detectable after an infection has resolved.
Therefore, a positive antibody result does not necessarily establish active infection.
For more information, visit Tick Boot Camp’s Lyme Disease Testing Resource.
PCR Testing for Lyme Disease
Dr. Shor discusses polymerase chain reaction (PCR) testing as an approach that detects genetic material from microorganisms.
PCR can be useful for diagnosing certain infections when performed on appropriate specimens.
Unlike antibody testing, PCR attempts to detect pathogen DNA directly.
However, detecting DNA does not always establish that living organisms are present or that an infection is currently active.
PCR testing for Lyme disease also has important limitations, including variable sensitivity depending on the specimen and clinical presentation.
A negative PCR result cannot reliably exclude Lyme disease in many circumstances.
Dr. Shor believes molecular testing represents an important area for continued diagnostic development.
FISH Testing and Direct Detection
Another technology discussed is fluorescence in situ hybridization (FISH).
FISH uses fluorescent probes designed to identify specific genetic sequences.
Dr. Shor describes this approach as another method for investigating infectious organisms.
Although FISH has established applications in laboratory medicine, its performance for diagnosing particular tick-borne infections depends on the specific assay and organism.
Not all specialty FISH tests have established clinical utility.
Results should be interpreted alongside other medical findings rather than treated as automatically definitive evidence of active infection.
Urine Antigen Testing and the Nanotrap Technology
Dr. Shor also discusses emerging antigen detection methods.
He specifically references Nanotrap technology, which has been investigated as a method for concentrating and detecting pathogen-associated proteins in biological samples.
During the interview, he describes research involving urine-based testing.
The appeal of urine antigen testing is that it may offer a relatively convenient way to investigate the presence of microbial components.
Dr. Shor explains that he participated in early research related to this technology.
However, detecting microbial antigens does not automatically establish viable organisms or active infection.
Urine antigen testing for Lyme disease remains an area of investigation and is not a replacement for established diagnostic approaches.
Additional independent validation is necessary to determine how these methods should be used in clinical practice.
Defining Chronic Lyme Disease: Dr. Shor’s Research Contributions
One of Dr. Shor’s most important research contributions is his role as lead author of the 2019 publication:
Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group
Published in the peer-reviewed journal Antibiotics, the paper proposes an ILADS definition of chronic Lyme disease.
The authors describe chronic Lyme disease as a multisystem illness involving persistent or recurring symptoms associated with ongoing Borrelia infection.
The proposed definition includes both previously untreated and previously treated patients.
The publication was intended to clarify terminology, support future research, and encourage greater recognition of patients experiencing prolonged illness.
The definition reflects ILADS’ interpretation of the evidence.
The cause of persistent symptoms following recommended Lyme disease treatment remains an area of scientific debate, and other medical organizations distinguish post-treatment Lyme disease syndrome from confirmed active infection.
Read the 2019 ILADS Working Group publication on chronic Lyme disease.
For related patient education, explore Tick Boot Camp’s Lyme Persists Resource.
Why Persistent Lyme Disease Symptoms Deserve Continued Research
Dr. Shor’s career reflects a longstanding interest in patients whose symptoms continue despite previous medical evaluation or treatment.
These patients may experience fatigue, pain, cognitive difficulties, sleep disturbances, and reduced daily functioning.
Persistent symptoms can significantly affect employment, relationships, independence, and quality of life.
Researchers continue investigating multiple possible explanations, including immune changes, tissue injury, autonomic dysfunction, other medical conditions, and whether persistent infection contributes in some circumstances.
Dr. Shor believes research into chronic Lyme disease and associated infections remains essential.
His work highlights the importance of developing better diagnostic tools, evaluating treatments rigorously, and taking patients’ experiences seriously.
Patients deserve validation and continued medical investigation even when the cause of their symptoms remains uncertain.
Honoring Dr. Sam Shor: The 2025 Pioneer in Lyme Award
The interview concludes with a special moment.
Rich congratulates Dr. Shor on being recognized at the 2025 ILADS conference.
Dr. Shor explains that he is receiving an award honoring his contributions to the Lyme disease community.
The International Lyme and Associated Diseases Educational Foundation (ILADEF) officially identifies Dr. Samuel M. Shor as the recipient of its 2025 Pioneer in Lyme Award.
The award recognizes professionals who have made significant contributions to advancing Lyme disease research, medical education, and patient care.
Dr. Shor reflects on the recognition with gratitude.
He discusses his years of involvement with ILADS, including his service as president and his work developing a published definition of chronic Lyme disease.
For Rich, the interview represents an opportunity to thank a physician whose contributions have helped shape the Lyme disease community.
The recognition celebrates not only Dr. Shor’s professional accomplishments but also his commitment to patients who have struggled to find answers.
Learn more about the ILADEF Pioneer in Lyme Award and its recipients.
Key Takeaways From Dr. Sam Shor
- Dr. Shor has studied chronic fatigue and Lyme disease for decades. His interest began in the late 1980s.
- Persistent symptoms deserve serious medical attention. Patients with prolonged fatigue and other disabling symptoms need thoughtful evaluation.
- Nutraceuticals are an area of clinical interest. Dr. Shor discusses their use alongside conventional treatment, although effectiveness varies and evidence remains limited.
- Disulfiram has demonstrated laboratory activity against Borrelia. Its clinical role in Lyme disease remains investigational, with important safety concerns.
- Coinfections can complicate tick-borne illness. Borrelia, Bartonella, and Babesia require different diagnostic and treatment considerations.
- Migrating joint pain can be associated with Lyme disease. It is one potential clinical clue, not a standalone diagnostic criterion.
- Bartonella symptoms are an evolving research topic. Dr. Shor discusses foot pain and urinary symptoms as observations from his practice.
- Babesiosis may cause significant sweating and systemic illness. Symptoms and appropriate laboratory testing guide evaluation.
- Lyme disease testing has limitations. Test performance varies by method, disease stage, and specimen.
- Molecular and antigen testing remain important research areas. PCR, FISH, and Nanotrap technologies have different capabilities and limitations.
- Dr. Shor helped develop an ILADS definition of chronic Lyme disease. His 2019 publication contributed to ongoing discussions about persistent illness.
- His contributions were recognized with the 2025 Pioneer in Lyme Award. The honor reflects decades of work in research, education, and patient advocacy.
Resources Mentioned in This Episode
Dr. Samuel Shor and His Research
- 2025 ILADEF Pioneer in Lyme Award – Dr. Samuel Shor
- Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group
- Dr. Shor’s Research Publication on PubMed
- Pilot Study of Disulfiram for Persistent Symptoms After Lyme Disease Treatment
Lyme Disease Education and Related Resources
- International Lyme and Associated Diseases Society (ILADS)
- Tick Boot Camp Lyme Disease Testing Resource
- Tick Boot Camp Lyme Persists Resource
- Tick Boot Camp Doctors Podcast Collection
- Tick Boot Camp Podcast – Patient Stories and Expert Interviews
About This LIVE from ILADS Episode
Recorded at the 2025 ILADS Conference in San Antonio, Texas, this episode features Dr. Samuel “Sam” Shor, MD, FILADS, a pioneering Lyme disease physician, researcher, and former ILADS president.
In conversation with Tick Boot Camp co-host Rich Johannesen, Dr. Shor discusses his decades of research into chronic fatigue syndrome and Lyme disease, the evolving use of nutraceuticals, investigations into disulfiram and Borrelia persister cells, and the clinical importance of recognizing possible coinfections involving Borrelia, Bartonella, and Babesia.
The conversation also explores Lyme disease diagnostic testing, including two-tier antibody testing, PCR, FISH, and emerging urine antigen technologies.
Dr. Shor reflects on his contributions to defining chronic Lyme disease and his recognition as the 2025 ILADEF Pioneer in Lyme Award recipient.
For people living with persistent symptoms and searching for answers, Dr. Shor’s story is a reminder that dedicated physicians and researchers continue working to advance understanding, improve diagnostic tools, and explore new approaches to care.




